Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
NUTX vs AMSF vs KNTK vs ADUS vs SGRY
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Specialty
Oil & Gas Midstream
Medical - Care Facilities
Medical - Care Facilities
NUTX vs AMSF vs KNTK vs ADUS vs SGRY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Insurance - Specialty | Oil & Gas Midstream | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $801M | $569M | $3.33B | $1.81B | $1.87B |
| Revenue (TTM) | $880M | $325M | $1.73B | $1.45B | $3.34B |
| Net Income (TTM) | $96M | $46M | $228M | $100M | $-76M |
| Gross Margin | 47.5% | 47.6% | 24.8% | 32.5% | 22.8% |
| Operating Margin | 31.4% | 17.8% | 8.2% | 9.8% | 11.8% |
| Forward P/E | 8.7x | 14.4x | 42.4x | 14.1x | 38.0x |
| Total Debt | $351M | $491K | $3.87B | $209M | $4.02B |
| Cash & Equiv. | $186M | $62M | $4M | $82M | $240M |
NUTX vs AMSF vs KNTK vs ADUS vs SGRY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Nutex Health, Inc. (NUTX) | 100 | 9.5 | -90.5% |
| AMERISAFE, Inc. (AMSF) | 100 | 65.4 | -34.6% |
| Kinetik Holdings In… (KNTK) | 100 | 136.2 | +36.2% |
| Addus HomeCare Corp… (ADUS) | 100 | 115.4 | +15.4% |
| Surgery Partners, I… (SGRY) | 100 | 28.0 | -72.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NUTX vs AMSF vs KNTK vs ADUS vs SGRY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NUTX carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 82.4%, EPS growth 7.9%, 3Y rev CAGR 58.6%
- 82.4% revenue growth vs AMSF's 2.6%
- Lower P/E (8.7x vs 38.0x)
- 10.5% ROA vs SGRY's -0.9%, ROIC 38.0% vs 4.1%
AMSF is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 0.23, Low D/E 0.2%, current ratio 0.32x
- 14.3% margin vs SGRY's -2.3%
- Beta 0.23 vs NUTX's 2.01, lower leverage
KNTK ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 3 yrs, beta 0.60, yield 16.5%
- Beta 0.60, yield 16.5%, current ratio 0.69x
- 16.5% yield, 3-year raise streak, vs AMSF's 8.4%, (3 stocks pay no dividend)
- +28.0% vs SGRY's -38.2%
ADUS is the clearest fit if your priority is long-term compounding.
- 399.9% 10Y total return vs AMSF's 31.8%
Among these 5 stocks, SGRY doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 82.4% revenue growth vs AMSF's 2.6% | |
| Value | Lower P/E (8.7x vs 38.0x) | |
| Quality / Margins | 14.3% margin vs SGRY's -2.3% | |
| Stability / Safety | Beta 0.23 vs NUTX's 2.01, lower leverage | |
| Dividends | 16.5% yield, 3-year raise streak, vs AMSF's 8.4%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +28.0% vs SGRY's -38.2% | |
| Efficiency (ROA) | 10.5% ROA vs SGRY's -0.9%, ROIC 38.0% vs 4.1% |
NUTX vs AMSF vs KNTK vs ADUS vs SGRY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NUTX vs AMSF vs KNTK vs ADUS vs SGRY — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KNTK leads in 2 of 6 categories
NUTX leads 1 • AMSF leads 0 • ADUS leads 0 • SGRY leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — NUTX and AMSF each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SGRY is the larger business by revenue, generating $3.3B annually — 10.3x AMSF's $325M. AMSF is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to SGRY's -2.3%. On growth, AMSF holds the edge at +10.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $880M | $325M | $1.7B | $1.4B | $3.3B |
| EBITDAEarnings before interest/tax | $297M | $58M | $534M | $159M | $572M |
| Net IncomeAfter-tax profit | $96M | $46M | $228M | $100M | -$76M |
| Free Cash FlowCash after capex | $270M | $8M | $441M | $137M | $208M |
| Gross MarginGross profit ÷ Revenue | +47.5% | +47.6% | +24.8% | +32.5% | +22.8% |
| Operating MarginEBIT ÷ Revenue | +31.4% | +17.8% | +8.2% | +9.8% | +11.8% |
| Net MarginNet income ÷ Revenue | +11.0% | +14.3% | +13.2% | +6.9% | -2.3% |
| FCF MarginFCF ÷ Revenue | +30.7% | +2.5% | +25.5% | +9.5% | +6.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +10.3% | -7.5% | +7.7% | +4.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +154.7% | -8.5% | -2.4% | +17.2% | +6.7% |
Valuation Metrics
Evenly matched — NUTX and SGRY each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, AMSF trades at a 34% valuation discount to ADUS's 18.7x P/E. On an enterprise value basis, NUTX's 3.3x EV/EBITDA is more attractive than KNTK's 13.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $801M | $569M | $3.3B | $1.8B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $967M | $508M | $7.2B | $1.9B | $5.7B |
| Trailing P/EPrice ÷ TTM EPS | 12.84x | 12.27x | 18.43x | 18.67x | -23.46x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.73x | 14.42x | 42.44x | 14.12x | 37.99x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.93x | — |
| EV / EBITDAEnterprise value multiple | 3.27x | 8.53x | 13.14x | 12.52x | 10.00x |
| Price / SalesMarket cap ÷ Revenue | 0.92x | 1.80x | 1.89x | 1.28x | 0.57x |
| Price / BookPrice ÷ Book value/share | 2.15x | 2.30x | 1.04x | 1.65x | 0.52x |
| Price / FCFMarket cap ÷ FCF | 3.26x | 63.83x | 44.78x | 17.48x | 9.57x |
Profitability & Efficiency
NUTX leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
NUTX delivers a 22.2% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-2 for SGRY. AMSF carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KNTK's 1.32x. On the Piotroski fundamental quality scale (0–9), NUTX scores 7/9 vs KNTK's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +22.2% | +9.7% | +21.1% | +9.3% | -2.2% |
| ROA (TTM)Return on assets | +10.5% | +5.6% | +4.2% | +7.0% | -0.9% |
| ROICReturn on invested capital | +38.0% | +21.9% | +1.9% | +8.8% | +4.1% |
| ROCEReturn on capital employed | +43.2% | +16.8% | +2.5% | +10.9% | +5.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 4 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.83x | 0.00x | 1.32x | 0.19x | 1.14x |
| Net DebtTotal debt minus cash | $166M | -$61M | $3.9B | $127M | $3.8B |
| Cash & Equiv.Liquid assets | $186M | $62M | $4M | $82M | $240M |
| Total DebtShort + long-term debt | $351M | $491,000 | $3.9B | $209M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 9.13x | — | 5.98x | 14.45x | 1.35x |
Total Returns (Dividends Reinvested)
KNTK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KNTK five years ago would be worth $19,312 today (with dividends reinvested), compared to $224 for NUTX. Over the past 12 months, KNTK leads with a +28.0% total return vs SGRY's -38.2%. The 3-year compound annual growth rate (CAGR) favors KNTK at 24.7% vs SGRY's -25.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.2% | -18.3% | +37.4% | -8.7% | -6.2% |
| 1-Year ReturnPast 12 months | +14.6% | -29.2% | +28.0% | -13.4% | -38.2% |
| 3-Year ReturnCumulative with dividends | +74.8% | -24.8% | +93.9% | +16.3% | -59.2% |
| 5-Year ReturnCumulative with dividends | -97.8% | -18.9% | +93.1% | +0.0% | -72.3% |
| 10-Year ReturnCumulative with dividends | -97.8% | +31.8% | -33.5% | +399.9% | -0.6% |
| CAGR (3Y)Annualised 3-year return | +20.5% | -9.1% | +24.7% | +5.2% | -25.8% |
Risk & Volatility
Evenly matched — AMSF and KNTK each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMSF is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than NUTX's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KNTK currently trades 94.8% from its 52-week high vs SGRY's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.01x | 0.23x | 0.60x | 0.58x | 1.04x |
| 52-Week HighHighest price in past year | $193.07 | $48.54 | $51.11 | $124.44 | $24.18 |
| 52-Week LowLowest price in past year | $77.21 | $29.42 | $31.33 | $90.89 | $11.41 |
| % of 52W HighCurrent price vs 52-week peak | +69.7% | +62.4% | +94.8% | +78.2% | +59.2% |
| RSI (14)Momentum oscillator 0–100 | 59.7 | 34.2 | 51.3 | 49.3 | 63.3 |
| Avg Volume (50D)Average daily shares traded | 197K | 212K | 1.2M | 236K | 1.5M |
Analyst Outlook
KNTK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NUTX as "Buy", AMSF as "Buy", KNTK as "Buy", ADUS as "Buy", SGRY as "Buy". Consensus price targets imply 52.3% upside for NUTX (target: $205) vs -1.8% for KNTK (target: $48). For income investors, KNTK offers the higher dividend yield at 16.47% vs AMSF's 8.41%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $205.00 | $44.50 | $47.57 | $128.67 | $18.60 |
| # AnalystsCovering analysts | 2 | 6 | 15 | 15 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | +8.4% | +16.5% | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 3 | 2 | 0 |
| Dividend / ShareAnnual DPS | — | $2.55 | $7.98 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +2.1% | +5.3% | 0.0% | 0.0% |
KNTK leads in 2 of 6 categories (Total Returns, Analyst Outlook). NUTX leads in 1 (Profitability & Efficiency). 3 tied.
NUTX vs AMSF vs KNTK vs ADUS vs SGRY: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NUTX or AMSF or KNTK or ADUS or SGRY a better buy right now?
For growth investors, Nutex Health, Inc.
(NUTX) is the stronger pick with 82. 4% revenue growth year-over-year, versus 2. 6% for AMERISAFE, Inc. (AMSF). AMERISAFE, Inc. (AMSF) offers the better valuation at 12. 3x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Nutex Health, Inc. (NUTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NUTX or AMSF or KNTK or ADUS or SGRY?
On trailing P/E, AMERISAFE, Inc.
(AMSF) is the cheapest at 12. 3x versus Addus HomeCare Corporation at 18. 7x. On forward P/E, Nutex Health, Inc. is actually cheaper at 8. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — NUTX or AMSF or KNTK or ADUS or SGRY?
Over the past 5 years, Kinetik Holdings Inc.
(KNTK) delivered a total return of +93. 1%, compared to -97. 8% for Nutex Health, Inc. (NUTX). Over 10 years, the gap is even starker: ADUS returned +399. 9% versus NUTX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NUTX or AMSF or KNTK or ADUS or SGRY?
By beta (market sensitivity over 5 years), AMERISAFE, Inc.
(AMSF) is the lower-risk stock at 0. 23β versus Nutex Health, Inc. 's 2. 01β — meaning NUTX is approximately 772% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 132% for Kinetik Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NUTX or AMSF or KNTK or ADUS or SGRY?
By revenue growth (latest reported year), Nutex Health, Inc.
(NUTX) is pulling ahead at 82. 4% versus 2. 6% for AMERISAFE, Inc. (AMSF). On earnings-per-share growth, the picture is similar: Kinetik Holdings Inc. grew EPS 157. 8% year-over-year, compared to -14. 5% for AMERISAFE, Inc.. Over a 3-year CAGR, NUTX leads at 58. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NUTX or AMSF or KNTK or ADUS or SGRY?
AMERISAFE, Inc.
(AMSF) is the more profitable company, earning 14. 9% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUTX leads at 31. 5% versus 9. 3% for KNTK. At the gross margin level — before operating expenses — NUTX leads at 50. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NUTX or AMSF or KNTK or ADUS or SGRY more undervalued right now?
On forward earnings alone, Nutex Health, Inc.
(NUTX) trades at 8. 7x forward P/E versus 42. 4x for Kinetik Holdings Inc. — 33. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUTX: 52. 3% to $205. 00.
08Which pays a better dividend — NUTX or AMSF or KNTK or ADUS or SGRY?
In this comparison, KNTK (16.
5% yield), AMSF (8. 4% yield) pay a dividend. NUTX, ADUS, SGRY do not pay a meaningful dividend and should not be held primarily for income.
09Is NUTX or AMSF or KNTK or ADUS or SGRY better for a retirement portfolio?
For long-horizon retirement investors, AMERISAFE, Inc.
(AMSF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), 8. 4% yield). Nutex Health, Inc. (NUTX) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMSF: +31. 8%, NUTX: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NUTX and AMSF and KNTK and ADUS and SGRY?
These companies operate in different sectors (NUTX (Healthcare) and AMSF (Financial Services) and KNTK (Energy) and ADUS (Healthcare) and SGRY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NUTX is a small-cap high-growth stock; AMSF is a small-cap deep-value stock; KNTK is a small-cap high-growth stock; ADUS is a small-cap high-growth stock; SGRY is a small-cap quality compounder stock. AMSF, KNTK pay a dividend while NUTX, ADUS, SGRY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.